Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03947957
Other study ID # BEACH (29BRC19.0065)
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date October 2, 2020
Est. completion date July 2026

Study information

Verified date April 2024
Source University Hospital, Brest
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to evaluate the predictive nature of the biomarker Porphyromonas catoniae measured at the age of 12 months in the occurrence of colonization with Pseudomonas aeruginosa at 36 months of age in children with cystic fibrosis.


Description:

This is a multicentric study in 3 phases: - Pre-inclusion: at the first visit to the CRCM (support for a positive screening confirmed by sweat test and genotyping CFTR) - Inclusion: possible between the 2nd visit to the CRCM (about 2 months old) and the 6th month - Follow-up: up to 36 months old. The pace of visits will be based on the usual follow-up rate of CF infants The clinical data as well as samples (expectorations, stools) will be collected on a monthly basis up to 6 months old and then every 2 months until one year old and finally quarterly until 3 years old. - Tracheo-bronchial secretions will be collected at the CRCM - Stools samples will be carried out by the parents prior to consultation with the CRCM - A blood collection will be carried out annually in an annual report.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 70
Est. completion date July 2026
Est. primary completion date July 2026
Accepts healthy volunteers No
Gender All
Age group 2 Months to 6 Months
Eligibility Inclusion criteria: - Infants aged 6 months maximum at inclusion with a confirmed diagnosis of cystic fibrosis in its classical form (positive sweat test and/or two mutations of the CFTR gene from class I to III) - Children free from any antecedent of colonization to P. aeruginosa at the time of inclusion (certified by the microbiological history supplemented by a molecular test by qPCR according to the diagram of Le gal et al., 2013)-Affiliation to the social security system - Consent signed by the holders of parental authority or the sole parent holding parental authority / and "oral" agreement of the second holder Exclusion criteria: - Severe acute pathology (other than cystic fibrosis) in progress, or requiring surgery - Children unable to undergo the tests required for the Protocol - Children whose parent (s) is (are) minor (s) - Children whose parental authority does not master the French language - Refusal to participate in the study

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
collection of expectoration, stools and blood
collection of expectoration, stools and blood

Locations

Country Name City State
France CHRU Angers Angers
France Hôpital des Enfants Bordeaux Bordeaux
France CHU Grenoble Grenoble
France Hôpital Femme-Mère-Enfant Lyon Lyon
France CHRU Nantes Nantes
France Hôpital Necker Paris
France Hôpital Trousseau Paris
France CHRU Rennes Rennes
France Centre de Perharidy Roscoff
France Hôpital Charles Nicolle Rouen Rouen
France CHRU de Tours Tours

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Brest

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Presence of P. aeruginosa in bacterial sputum cultures collected at 36 months of age positive or negative 36 months
Secondary Absolute amount of P. aeruginosa at different sampling times. amount (UFC/mL) 36 months
Secondary Absolute amount of P. catoniae in respiratory secretions at different sampling times and Delta between 12, 24 and 36 months. amount (UFC/mL) 36 months
Secondary Absolute amount of P. catoniae in stool at different sampling times and Delta between 12, 24 and 36 months. amount (UFC/mL) 36 months
Secondary Level of dysbiosis 36 months
See also
  Status Clinical Trial Phase
Completed NCT04696198 - Thoracic Mobility in Cystic Fibrosis Care N/A
Completed NCT00803205 - Study of Ataluren (PTC124™) in Cystic Fibrosis Phase 3
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03601637 - Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del Phase 3
Terminated NCT02769637 - Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
Recruiting NCT06012084 - The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis N/A
Recruiting NCT06032273 - Lung Transplant READY CF 2: CARING CF Ancillary RCT N/A
Recruiting NCT06030206 - Lung Transplant READY CF 2: A Multi-site RCT N/A
Recruiting NCT05392855 - Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF) N/A
Recruiting NCT06088485 - The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
Recruiting NCT04039087 - Sildenafil Exercise: Role of PDE5 Inhibition Phase 2/Phase 3
Recruiting NCT04056702 - Impact of Triple Combination CFTR Therapy on Sinus Disease.
Completed NCT04058548 - Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation N/A
Completed NCT04038710 - Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
Completed NCT03637504 - Feasibility of a Mobile Medication Plan Application in CF Patient Care N/A
Recruiting NCT03506061 - Trikafta in Cystic Fibrosis Patients Phase 2
Completed NCT03566550 - Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
Recruiting NCT04828382 - Prospective Study of Pregnancy in Women With Cystic Fibrosis
Completed NCT04568980 - Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
Recruiting NCT04010253 - Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis N/A